Parp Inhibitor Ovarian Cancer Side Effects

Evidence experience and clinical potential t evans and u.

Parp inhibitor ovarian cancer side effects.

Parp inhibitors are an effective and promising treatment for ovarian cancers but they still bring with them the risk of some side effects you should discuss with your doctor. Introduction poly adp ribose polymerase parp inhibitors are a class of oral anticancer medications that have the most evidence for use in patients with inherited germline mutations. Findings from the prima trial were published september 28 in the new england journal of medicine. They are developed for multiple indications including the treatment of heritable cancers.

Fatigue is a common side effect and is reported with all three parp inhibitors 3 11 14 when a patient receiving a parp inhibitor complains of fatigue it is important to rule out other contributing factors such as disease related fatigue depression insomnia and anemia as well as sedation from concomitant medications. Parp inhibitors in ovarian cancer. Yet investigators state the drug is well tolerated. A phase i ii study of the oral parp inhibitor rucaparib in patients with germline brca1 2 mutated ovarian carcinoma or other solid tumors.

Ursula matulonis chief of gynecologic oncology at the dana farber cancer institute to learn more about these potential side effects. Parp inhibitors can affect blood cells and the most common serious side effects of niraparib were lower than normal levels of red blood cells anemia platelets thrombocytopenia and white blood cells neutropenia. Nausea was common affecting 76 of. Clin cancer res 2017 23 15 4095 4106.

Here two oncology pharmacists discuss the side effects of parp inhibitor treatment and how to prevent and treat nausea and vomiting in this patient population. National comprehensive cancer network nccn ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Parp inhibitors in. We spoke to dr.

Parp inhibitors rs meehan and ap chen gynecologic oncology research and practice 2016. Volume 3 issue 3. New treatment option for ovarian cancer. The race is on js brown and others british journal of cancer 2016.

Several forms of cancer are more dependent on parp than regular cells making parp parp1 parp2 etc an attractive target for cancer therapy parp inhibitors appear to improve progression free. Parp inhibitors are a group of pharmacological inhibitors of the enzyme poly adp ribose polymerase parp.